The prognostic value of POD24 in relapsed/refractory follicular lymphoma-A SCHOLAR-5 analysis.

ABSTRACT:

Introduction

Follicular lymphoma (FL) has a heterogeneous prognosis. Progression within 24 months of starting front-line therapy (POD24) is prognostic of overall survival (OS). Despite its prognostic value in early lines, the role of POD24 in relapsed/refractory (R/R) patients initiating later lines of therapy (LoTs) is unknown.

Methods

We analyzed the SCHOLAR-5 real-world cohort to investigate whether POD24 is prognostic in patients with R/R FL initiating ≥3rd LoT.

Results

Among the 128 SCHOLAR-5 patients, 34 patients experienced POD24. POD24 patients received their ≥3 LoT after a shorter time compared with non-POD24 patients (median 42.0 months [range: 8.8‒17.8] vs. 109.9 months [range: 29.6‒310.2]). Using a time-dependent multivariate Cox model, POD24 was predictiv

SUBMITTER: Limbrick-Oldfield EH 

PROVIDER: S-EPMC11800366 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature